Lineage price target lowered to $39 from $46 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Lineage (LINE) to $39 from $46 and keeps an Equal Weight rating on the shares. There is potential downside risk to consensus 2026 AFFO and core EBITDA estimates, as supply-demand imbalances continue to pressure results, the analyst tells investors in a research note. The pace of demand recovery remains the key driver of upside versus downside risk, the firm says.